Drug Trial Radar · NCT04950075
Study of INBRX-109 in Conventional Chondrosarcoma
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
206
Actual
Start
Sep 23, 2021
Primary completion
Sep 30, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Inhibrx Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Conditions
- Conventional Chondrosarcoma
Interventions
INBRX-109Drug
Tetravalent DR5 Agonist Antibody
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival per RECISTv1.1 by real time IRR comparing INBRX-109 and placeboTime frame: 3 years
Locations
68 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center
Phoenix, Arizona
Precision NextGen Oncology & Research Center
Beverly Hills, California
University of California, San Francisco (UCSF)
San Francisco, California
Sarcoma Oncology Center
Santa Monica, California
University of Colorado
Denver, Colorado
Yale Cancer Center
New Haven, Connecticut
Mayo Clinic - Jacksonville
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Northwestern University - Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois
Rush Cancer Center
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Johns Hopkins
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School of Medicine - St. Louis
St Louis, Missouri
Nebraska Methodist Hospital
Omaha, Nebraska
Norris Cotton Cancer Center
Lebanon, New Hampshire
Memorial Sloan Kettering Cancer Center
New York, New York
Columbia University
New York, New York
Duke University
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
University of Oklahoma - Stephenson Cancer Center
Oklahoma City, Oklahoma
Oregon Health & Science University (OHSU) Knight Cancer Institute
Portland, Oregon
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
University of Washington
Seattle, Washington
Royal Adelaide Hospital
Adelaide, Australia
Chris O'Brien Lifehouse
Camperdown, Australia
Princess Alexandra Hospital
Woolloongabba, Australia
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
AP-HM - Hôpital de la Timone
Marseille, France
ICM - Institut Regional du Cancer de Montpellier
Montpellier, France
Centre Antoine-Lacassagne
Nice, France
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.